Jiangsu Recbio Technology Co., Ltd.

2179

CNE1000057K9

Pharmaceuticals

End-of-day quote Hong Kong S.E. Other stock markets 06:00:00 2024-04-25 pm EDT			5-day change	1st Jan Change
9.13 ^CNY	0.00%		-1.72%	-15.93%

Mar. 27	Jiangsu Recbio Technology Co., Ltd. and Shanghai Rongsheng Biotech Co.,Ltd. Sign Strategic Cooperation Agreement on the New Adjuvant Vaccine Project	CI
Mar. 21	Jiangsu Recbio Technology's Loss Narrows in 2023	MT

Jiangsu Recbio Technology Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022

March 20, 2023 at 09:42 am EDT

Jiangsu Recbio Technology Co., Ltd. reported earnings results for the full year ended December 31, 2022. For the full year, the company reported net loss was CNY 722.7 million compared to CNY 657.56 million a year ago. Basic loss per share from continuing operations was CNY 1.52 compared to CNY 1.56 a year ago.

Latest news about Jiangsu Recbio Technology Co., Ltd.

Jiangsu Recbio Technology Co., Ltd. and Shanghai Rongsheng Biotech Co.,Ltd. Sign Strategic Cooperation Agreement on the New Adjuvant Vaccine Project	Mar. 26	CI
Jiangsu Recbio Technology's Loss Narrows in 2023	Mar. 21	MT
Jiangsu Recbio Technology Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 20	CI
Jiangsu Recbio Technology Co., Ltd. Announces Positive Results in the Interim Analysis of the Clinical Trial of Recbio's Novel Adjuvanted Recombinant Shingles Vaccine REC610 in the Philippines	Dec. 28	CI
Jiangsu Recbio Logs Positive Results from Philippines Trial Of Shingles Vaccine	Dec. 29	MT
Jiangsu Recbio Technology to Extend Validity Period of Share Sale	Dec. 28	MT
Jiangsu Recbio Technology Co., Ltd.(SEHK:2179) added to S&P Global BMI Index	23-09-18	CI
Jiangsu Recbio Technology Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-25	CI
China Approves Recbio's Clinical Trial Application for Shingles Vaccine	23-07-26	MT
Jiangsu Recbio Technology Co., Ltd. Announces Acceptance of Clinical Trial Application for the Novel Adjuvanted Recombinant Shingles Vaccine REC610 in China and Overseas Clinical Trial Progress	23-07-26	CI
Jiangsu Recbio Technology Selected for Morgan Stanley Capital International China Small Cap Index	23-05-17	MT
Jiangsu Recbio Technology Co., Ltd. Announces Directorate Appointments	23-05-11	CI
Chinese Securities Regulator Approves Jiangsu Recbio Technology's Share Issuance; Stock Sinks 3%	23-04-20	MT
Pfizer signs strategic cooperation pact with China's Sinopharm	23-04-13	RE
Jiangsu Recbio Technology Co., Ltd. Announces Resignation of Feng Tao as Non-Executive Director and A Member of the Nomination Committee	23-04-03	CI
Certain H Shares of Jiangsu Recbio Technology Co., Ltd. are subject to a Lock-Up Agreement Ending on 30-MAR-2023.	23-03-29	CI
Mongolia Grants Emergency Approval for Jiangsu Recbio's Recombinant COVID-19 Vaccine	23-03-21	MT
Jiangsu Recbio Technology Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-20	CI
Jiangsu Recbio Technology Co., Ltd. Announces Resignation of Directors	23-03-20	CI
Jiangsu Recbio Completes Subject Enrollment for Vaccine Clinical Trial	23-02-13	MT
Jiangsu Recbio Technology Co., Ltd. Announces Completion of the First Batch of Subject Enrollment for the Phase I Clinical Trial of Novel Adjuvanted Recombinant Shingles Vaccine REC610	23-02-13	CI
China's Securities Regulator Accepts Jiangsu Recbio's Application for Shares Issuance	23-02-08	MT
Merck's COVID treatment expected to launch in China on Friday	23-01-11	RE
Jiangsu Recbio Receives Positive Results for Phase II Study of COVID-19 Vaccine in the Philippines	22-12-27	MT
Jiangsu Recbio Technology Co., Ltd. Achieves Positive Results for its Sequential Booster Vaccination Phase II Study of the Recombinant Two-Component COVID-19 Vaccine ReCOV in the Philippines	22-12-25	CI

Chart Jiangsu Recbio Technology Co., Ltd.

Duration

Period

Chart Jiangsu Recbio Technology Co., Ltd.

More charts

Company Profile

Jiangsu Recbio Technology Co Ltd is a China-based company mainly engaged in the research and development of vaccines. The Company has a portfolio of clinical-stage and pre-clinical stage vaccines, and its human papilloma virus (HPV) vaccine pipelines comprise of recombinant HPV 9-valent vaccine REC603, recombinant HPV 9-valent vaccines REC601 and REC602, recombinant HPV quadrivalent vaccine REC604a, and recombinant HPV 9-valent vaccine REC604b. The Company also involves in the development of Covid-19 vaccines. The Company mainly distributes products within domestic market.

Sector

Pharmaceuticals

Calendar

2024-08-22 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

8.451 CNY

Average target price

13.79 CNY

Spread / Average Target

+63.15%

Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Biopharmaceuticals

	1st Jan change	Capi.
JIANGSU RECBIO TECHNOLOGY CO., LTD.	-15.93%	559M
CSL LIMITED	-4.66%	86.13B
SAMSUNG BIOLOGICS CO.,LTD.	+1.32%	39.82B
BIOGEN INC.	-19.27%	30.42B
UCB	+57.86%	25.23B
BIOMARIN PHARMACEUTICAL INC.	-16.09%	15.35B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.	-9.14%	11.95B
INCYTE CORPORATION	-17.69%	11.6B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.	-43.00%	11.51B
SWEDISH ORPHAN BIOVITRUM AB	+5.24%	8.71B

Biopharmaceuticals